Taiko Pharmaceutical: Announcement: The transcript article of the Q2 (interim) earnings conference for the fiscal year ending December 2024 has been published on LogMe Finance.
Taiko Pharmaceutical: Summary of the Q2 2024 financial statements.
Taiko Pharmaceutical: Summary of financial results for the 1st quarter of 2024
Taiko Pharmaceutical: Plans for compliance with listing maintenance standards
Taiko Pharmaceutical: Independent Officer Registration Form
Taiko Pharmaceutical: Notice regarding changes in officers
Taiko Pharmaceutical: Notice regarding a decrease in the amount of capital (capital reduction)
Taiko Pharmaceutical: Summary of Financial Results 2023
Taiko Pharmaceutical: Notice regarding completion of exercise of stock acquisition rights with exercise price amendment clauses and monthly exercise status
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clauses
Taiko Pharmaceutical: Notice Concerning Continued Reduction in Executive Remuneration
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause
Taiko Pharmaceutical: Notice regarding the establishment of the Nomination and Remuneration Committee
Taiko Pharmaceutical: Summary of Financial Results for the third quarter 2023
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clauses
Taiko Pharmaceutical: Notice Concerning Mass Exercise of Stock Acquisition Rights with Exercise Price Amendment Clause
Taiko Pharmaceutical: Summary of Financial Results for the second quarter 2023
Taiko Pharmaceutical: Notice Concerning the Monthly Exercise Status of Stock Acquisition Rights with Exercise Price Amendment Clause
No Data
No Data